Efficacy of budesonide/formoterol maintenance and reliever therapy compared with higher-dose budesonide as step-up from low-dose inhaled corticosteroid treatment.

In the group using reliever on <1 occasion/day at baseline, there was a 35% reduction in severe exacerbations for BUD/FORM MRT versus fixed-dose BUD (mean 0.09 vs 0.14 severe exacerbations per year, respectively; Table 2 ), but this effect did not reach statistical significance (rate ratio = 0.65 [95% CI: 0.38, 1.11]; p = 0.11; Fig. 1 ).

also in 111,027 other papers